C4 Therapeutics upgraded by Wells Fargo with a new price target

12/19/24 7:32:29 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Wells Fargo upgraded C4 Therapeutics from Equal Weight to Overweight and set a new price target of $12.00 from $8.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CCCC

Date	Price Target	Rating	Analyst
12/19/2024	$8.00 → $12.00	Equal Weight → Overweight	Wells Fargo
11/18/2024	$4.00	Equal-Weight	Stephens
1/29/2024	$6.00	Underweight → Neutral	JP Morgan
12/13/2023	$2.00 → $12.00	Hold → Buy	Stifel
2/24/2023	$12.00 → $10.00	Underperform → Neutral	Credit Suisse
2/24/2023	$15.00 → $5.00	Neutral → Underweight	JP Morgan
11/4/2022	$22.00 → $15.00	Overweight → Neutral	JP Morgan
10/11/2022	$6.00	Underweight	Morgan Stanley